Plasma Very Long Chain Fatty Acids

The Plasma Very Long Chain Fatty Acids (VLCFA) test is a biochemical test primarily used to diagnose peroxisomal disorders, most notably X-linked adrenoleukodystrophy (X-ALD). These conditions result from impaired breakdown of VLCFAs due to enzyme deficiencies, leading to accumulation of these fatty acids in the body. The test measures levels of specific long-chain fatty acids in the blood to identify abnormal elevations that are indicative of metabolic disorders affecting lipid metabolism.

This test is usually ordered in individuals—especially children—who show signs of neurological regression, adrenal insufficiency, or other symptoms suggestive of metabolic or peroxisomal disorders. It may also be used in newborn screening programs or to assess family members of individuals already diagnosed with conditions like ALD. Timely diagnosis can help initiate appropriate monitoring and supportive treatment strategies.

The test requires a blood sample drawn from a vein, usually in the arm. After collection, the blood is processed to separate the plasma, where fatty acids are measured using techniques such as gas chromatography-mass spectrometry (GC-MS). The accuracy of this test depends on proper sample handling, so timely processing and transport to the lab is essential.

Elevated levels of VLCFAs in plasma suggest a defect in peroxisomal beta-oxidation, which is characteristic of disorders such as adrenoleukodystrophy or Zellweger spectrum disorders. The specific pattern of fatty acids—like C24:0 and C26:0 ratios—can provide clues about the underlying disorder. While this test is diagnostic, further genetic testing may be needed to confirm the exact type of metabolic disorder.

If the results are abnormal, genetic counseling and molecular testing are typically recommended to confirm the diagnosis and identify specific gene mutations. Based on the diagnosis, further evaluations such as adrenal function tests, neurological assessments, or MRI scans may be performed. In families with a known history of peroxisomal disorders, siblings or relatives may also be tested for carrier status or early detection.